Sin Nombre Virus: North American Hantavirus and the Four Corners Outbreak
Sin Nombre virus (SNV) is the dominant North American hantavirus, vectored by deer mice. History, 1993 Four Corners outbreak, current US case load, mortality near 36%.
Sin Nombre virus (SNV) is the dominant cause of Hantavirus Pulmonary Syndrome in North America. Identified during the 1993 Four Corners outbreak in the Arizona–Colorado–New Mexico–Utah quadripoint, SNV was the first New World hantavirus to be characterized at a molecular level and established that the genus could cause acute pulmonary disease rather than the renal syndrome seen in Eurasia.
The 1993 Four Corners outbreak
In May 1993, a cluster of previously healthy Navajo (Diné) adults presented at hospitals in the Four Corners region with rapidly progressive non-cardiogenic pulmonary edema. The case-fatality rate of the initial 17 cases was 76%. Within weeks, CDC and the University of New Mexico identified a novel hantavirus and traced it to Peromyscus maniculatus, the deer mouse. Retrospective serosurveys showed SNV had been circulating undetected in North America for decades; the cluster reflected a population explosion of deer mice driven by an El Niño year of abundant piñon nuts.
Reservoir and ecology
The deer mouse is one of the most widely distributed mammals in the Western Hemisphere, ranging from Alaska to southern Mexico. SNV seroprevalence in deer-mouse populations averages 10–15% and can exceed 30% in outbreak years. Population dynamics correlate strongly with primary productivity: precipitation, mast (piñon and oak), and winter mildness all amplify rodent density and human spillover.
Geographic distribution of human cases
| State | Cumulative cases (1993–2024) | Case-fatality |
|---|---|---|
| New Mexico | ~120 | ~38% |
| Colorado | ~115 | ~36% |
| Arizona | ~85 | ~33% |
| Washington | ~52 | ~30% |
| California | ~80 | ~34% |
| Texas | ~45 | ~36% |
| Utah | ~40 | ~37% |
Source: aggregated CDC HPS surveillance reports through 2024. Annual US case counts since 2000 have hovered between 25 and 45.
Clinical features
SNV-HPS is clinically near-identical to Andes-virus HPS: a 2–8 week incubation, prodromal myalgia and fever, then abrupt cardiopulmonary decompensation. Distinguishing features:
- Slightly later onset of pulmonary symptoms relative to ANDV (median day 5–6 vs day 4).
- No documented person-to-person transmission — the principal contrast with Andes virus.
- Cardiac involvement is profound; troponin elevation and reduced ejection fraction are common.
Diagnosis and treatment
Diagnosis relies on IgM ELISA and confirmatory RT-PCR. Treatment is supportive: protective lung ventilation, conservative fluids, early vasopressors. ECMO at experienced centers (UNM, Harborview) has driven observed CFR for transferred patients well below 30%.
Why SNV matters in 2026
Background SNV transmission in the US is steady. The 2026 signal of interest is whether public concern over Andes virus will alsoelevate clinical recognition of SNV cases that today are missed as "atypical pneumonia." Preparedness planning at CDC and state health departments has already begun briefing front-line clinicians on the SNV/ANDV differential.
Compare against the South-American counterpart in the Andes virus profile, or revisit the syndrome differential in HPS vs HFRS.
Prevention checklist
- Trap-and-remove rodents around homes, sheds, vacation cabins.
- Wet-clean droppings — never sweep dry.
- Air out closed structures ≥30 minutes before entry.
- For occupational exposure (Forest Service, granary, agriculture), respiratory protection N95 minimum.
- Hikers and campers: avoid direct contact with rodent burrows; store food in sealed containers.
Frequently asked
What is Sin Nombre virus?
Sin Nombre virus (SNV) is the New World hantavirus species responsible for most cases of Hantavirus Pulmonary Syndrome in North America. Its reservoir is the deer mouse (Peromyscus maniculatus).
What was the Four Corners outbreak?
In May 1993, a cluster of severe pulmonary disease in the Four Corners region of the US southwest led to the discovery of SNV. The initial case-fatality rate was 76%, but contemporary care has lowered observed CFR to roughly 36%.
Can Sin Nombre virus spread person-to-person?
No. Unlike Andes virus, SNV has no documented human-to-human transmission. All confirmed cases trace back to direct or aerosol exposure to deer-mouse excreta.
How many Sin Nombre virus cases occur per year in the US?
Annual reported HPS cases in the US since 2000 range from 25 to 45, with the highest cumulative burden in New Mexico, Colorado, Arizona, California, and Washington.
Is there a treatment for Sin Nombre virus infection?
No specific antiviral is approved. Treatment is supportive critical care: lung-protective ventilation, conservative fluids, vasopressors, and ECMO at experienced tertiary centers.
Related explainers
- → Hantavirus — Complete GuideComprehensive guide to hantavirus: symptoms, transmission via rodents, HPS vs HFRS, mortality rates, treatment, and the 2026 outbreak signal.
- → Andes VirusAndes orthohantavirus (ANDV) is the only hantavirus confirmed for person-to-person spread. Distribution, mortality (~35%), 2026 cluster activity in Argentina and Chile.
This article is editorial research aggregated from public health authorities. It is not medical advice. For clinical concerns, consult a healthcare professional. Sources: WHO, CDC, ECDC, PAHO.